Navidea Biopharmaceuticals (NAVB) Release: FDA Approves Lymphoseek To Help Determine The Extent Of Head And Neck Cancer In The Body
6/13/2014 9:58:39 AM
The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body’s head and neck region.
Help employers find you! Check out all the jobs and post your resume.
comments powered by